AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Other Respiratory & Immunology medicines by Year
Other Respiratory & Immunology medicines — Worldwide product sales ($M) ($M)
AstraZeneca Other Respiratory & Immunology medicines: $274M in FY2025, down 31.5% from a year earlier.
Where the FY2025 figure comes from
“|| Other R&I | 274 | (31) | (32) | 75 | (55) | 133 | (21) | (21) | 59 | 2 | - | 7 | (5) | (2)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Respiratory & Immunology medicines — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 274 | -31.5% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 400 | +23.5% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 324 | -23.0% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 421 | -29.1% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 594 | +364.1% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 128 | -72.6% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 467 | -14.3% | Form 20-F (filed 2021-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 545 | +25.9% | Form 20-F (filed 2021-02-16) ↗ |
| FY2017 | Dec 31, 2017 | 433 | +37.0% | Form 20-F (filed 2020-03-03) ↗ |
| FY2016 | Dec 31, 2016 | 316 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up other Respiratory & Immunology medicines
- Other Respiratory & Immunology medicines — Worldwide YoY actual (%)-31.0% · FY2025
- Other Respiratory & Immunology medicines — Worldwide YoY CER (%)-32.0% · FY2025
- Other Respiratory & Immunology medicines — US product sales ($M)75 · FY2025
- Other Respiratory & Immunology medicines — Emerging Markets product sales ($M)133 · FY2025
- Other Respiratory & Immunology medicines — Europe product sales ($M)59 · FY2025
- Other Respiratory & Immunology medicines — Established RoW product sales ($M)7 · FY2025
Cite this data
StockData. (2026). AstraZeneca Other Respiratory & Immunology medicines ($M), annual FY2016–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-ri-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.